苯噻啶苹果酸盐 | 5189-11-7

• 物质功能分类: 生物化工 - 抑制剂 - 神经信号通路(Neuronal Signaling)
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环七噻吩
• 中文名称: 苯噻啶苹果酸盐
• 中文别名: 双氯芬酸苹果酸盐；9,10-二氢-4-(1-甲基哌啶-4-亚基)-4H-苯并[4,5]环庚烷并[1,2-b]噻吩苹果酸盐(1:1)；9,10-二氢-4-(1-甲基哌啶-4-亚基)-4H-苯并[4,5]环庚烷并[1,2-b]噻吩苹果酸盐 (1:1)
• 英文名称: Pizotifen malate
• 英文别名: 2-hydroxybutanedioic acid;1-methyl-4-(6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)piperidine
• CAS: 5189-11-7
• 化学式: C23H27NO5S
• 分子量: 429.5
• InChiKey: IWAWCPZVTXCFKD-UHFFFAOYSA-N

物化性质

• 熔点：
  185-186° (dec)
• 溶解度：
  酸水溶液（微溶，加热）、DMSO（微溶）、甲醇（微溶）
• 碰撞截面：
  174.4 Ų [M+H-H2O]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  3.28
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

生物活性

Pizotifen Malate (BC-105) 用于治疗经常性偏头痛。

靶点

• 5-HT_2A 受体
• 5-HT_1C 受体

体外研究

Pizotifen malate (BC-105 malate) 是一种强效的 5-HT₂受体拮抗剂，对 5-HT_1C结合位点有高亲和力。Pizotifen 是一个抗 5-HT_2A 受体拮抗剂，并且具有抑制血小板聚集的能力。

体内研究

所有给药剂量的 Pipethiadene 和 Pizotifen malate (BC-105 malate) 均显著降低了胎儿体重；Pipethiadene 在 0.6 和 1.2 mg/kg 剂量下以及中等剂量的 Pizotifen malate 下，胎盘重量显著降低。植入物、活胎、死胎和外胚层、骨骼和内脏畸形的发生率与对照组无显著差异；治疗小鼠骨髓细胞的染色体异常数不显著高于阴性对照组；微核试验未显示微核频率较对照组有所增加。在两个较高剂量下，Pipethiadene 和 Pizotifen malate 的有丝分裂指数低于对照组。

用途

本品为抗组胺类药物，用于治疗偏头痛。

文献信息

• Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors
  申请人：Amberg Wilhelm

  公开号：US20100184787A1

  公开（公告）日：2010-07-22

  The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders.

  该发明涉及一般式(I)的杂环取代胍胺化合物，以及其对映体、非对映体和/或互变异构体，以及其药学上可接受的盐和已知化合物的前药。该发明还涉及将所述杂环取代胍胺化合物用作5-HT5受体的结合伙伴，用于治疗和/或预防由5-HT5受体活性调节的疾病，特别是用于治疗和/或预防神经退行性和神经精神障碍，以及与该类障碍相关的症状、体征和功能障碍。
• USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE
  申请人：Smith-Swintosky Virginia L.

  公开号：US20070191461A1

  公开（公告）日：2007-08-16

  The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is directed to a method for the treatment and/or prevention of migraine, which includes mono-therapy and alternatively, co-therapy with at least anti-migraine agent

  本发明涉及一种治疗或预防偏头痛的方法，包括向需要的受试者投予根据本处定义的公式(I)的一种或多种新型苯并杂环磺酰胺衍生物的治疗有效量。本发明涉及一种治疗和/或预防偏头痛的方法，包括单独治疗和/或与至少一种抗偏头痛药物联合治疗。
• [EN] AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF<br/>[FR] AGONISTES ET ANTAGONISTES DU RÉCEPTEUR S1P5, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBOTT LAB

  公开号：WO2010093704A1

  公开（公告）日：2010-08-19

  Disclosed are compounds that are agonists or antagonists of the S1P5 receptor, compositions comprising said compounds, and methods of using said compounds and compositions. In certain embodiments, said compounds are 1-benzylazetidine-3-carboxylic acid derivatives. In certain embodiments, said methods relate to the treatment of neuropatic pain and/or a neurodegenerative disorder. In certain embodiments, said compounds may be used in combination with a second therapeutic agent.

  本文披露了作为S1P5受体激动剂或拮抗剂的化合物，包括含有这些化合物的组合物，以及使用这些化合物和组合物的方法。在某些实施例中，这些化合物是1-苄基氮杂环丙氨酸衍生物。在某些实施例中，这些方法涉及治疗神经痛和/或神经退行性疾病。在某些实施例中，这些化合物可以与第二治疗剂结合使用。
• HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：Amberg Wilhelm

  公开号：US20100041698A1

  公开（公告）日：2010-02-18

  The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.

  该发明涉及一般式（I）的化合物，其相应的对映体、异构体和/或互变异构体形式，以及其药学上可接受的盐和所述化合物的前药。该发明还涉及将所述化合物用作5-HT5受体的结合伙伴，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状和功能障碍。
• USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE
  申请人：Smith-Swintosky Virginia L.

  公开号：US20070191474A1

  公开（公告）日：2007-08-16

  The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment and/or prevention of migraine, which includes mono-therapy and alternatively, co-therapy with at least anti-migraine agent.

  本发明是一种治疗或预防偏头痛的方法，包括向需要的受试者施用一种或多种新型苯并杂环磺酰胺衍生物的治疗有效量，其化学式为(I)和(II)。本发明涉及一种治疗和/或预防偏头痛的方法，包括单独治疗，或与至少一种抗偏头痛药物联合治疗。